Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma

Modern research reportedly began with Israeli scientists Raphael Mechoulam and Yechiel Gaoni who, in 1964, isolated and identified tetrahydrocannabinol (THC).  

Mechoulam later also elucidated the chemical structure of several other components including cannabidiol (CBD), which the scientists found to be an intriguing, non-intoxicating molecule. 

They called these unique botanical compounds “cannabinoids,” likening the plant to “a pharmacological treasure trove.”

In the 1970s, Robert Hepler, MD, and Ira Frank, MD, explored the effects of on visual acuity in humans and discovered that cannabis had an unexpected effect of lowering intraocular pressure, a key risk factor in glaucoma. This led to a significant amount of research on the role of cannabinoids in the eye, which outside of the brain are the organs that contain the greatest number of cannabinoid receptors. However, at that time researchers were unable to find a way to effectively deliver a therapeutic dose of cannabis without avoiding its intoxicating effects.  

Jump ahead to 2022, and you’ll find unique and advanced studies conducted around the world, and by companies like San Diego’s Skye Bioscience Inc. (OTCQB: SKYE). The pharmaceutical company reports improving the effects of cannabinoid molecules by making molecular changes to the structure of a naturally occurring molecule to enhance its therapeutic benefit, through the endocannabinoid system, which is increasingly being shown to play a vital role in critical systems and functions in the …

Full story available on Benzinga.com

Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma on Benzinga